Compare BFC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | HROW |
|---|---|---|
| Founded | 1894 | 1998 |
| Country | United States | United States |
| Employees | N/A | 373 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2018 | N/A |
| Metric | BFC | HROW |
|---|---|---|
| Price | $155.29 | $39.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $157.00 | $69.86 |
| AVG Volume (30 Days) | 82.1K | ★ 548.8K |
| Earning Date | 04-16-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 11.23 | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.67 | $31.62 |
| Revenue Next Year | $2.01 | $50.77 |
| P/E Ratio | $85.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $115.29 | $28.54 |
| 52 Week High | $154.42 | $54.98 |
| Indicator | BFC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 64.11 | 42.50 |
| Support Level | $134.81 | $37.81 |
| Resistance Level | N/A | $41.82 |
| Average True Range (ATR) | 4.97 | 2.31 |
| MACD | 0.53 | -0.69 |
| Stochastic Oscillator | 91.09 | 20.53 |
Bank First Corp is a United States-based company engaged in providing financial services, a full range of consumer and commercial financial institution services to individuals and businesses, including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.